文献速递乳腺癌

皮下注射曲妥珠单抗治疗HER2阳性早期或局部晚期乳腺癌的安全性特征:SCHEARLY研究主要分析

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
PubMed 文献 · Eur J Cancer · 2018-11-03

SCHEARLY是一项前瞻性、两队列、非随机、多中心意大利研究,纳入240例HER2阳性早期或局部晚期乳腺癌患者,评估皮下注射曲妥珠单抗600 mg的安全性。安全性人群(N=228)中,≥3级治疗相关不良事件发生率为3.9%,严重不良事件为0.9%,心脏不良事件为14.5%,左心室射血分数下降为7.9%。研究结论为皮下注射曲妥珠单抗600 mg是安全可耐受的辅助/新辅助治疗选择。

要点

  • 安全性人群(N=228)中≥3级治疗相关不良事件发生率为3.9%,严重不良事件为0.9%。
  • 心脏不良事件发生率为14.5%,最常见为左心室射血分数下降(7.9%),未发生充血性心力衰竭。
  • 全身给药相关反应发生率为68.0%,局部注射部位反应为21.9%,大多为1-2级。

核心结论

  • 皮下注射曲妥珠单抗600 mg被确认为HER2阳性早期和局部晚期乳腺癌患者辅助/新辅助治疗的安全且可耐受的选择。

研究设计与样本

  • SCHEARLY是一项前瞻性、两队列、非随机、多中心意大利研究,属于UmbHER1伞式研究,计划进行为期1年的皮下注射曲妥珠单抗600 mg治疗。
  • 患者依次分配至队列A(N=121)接受手持注射器给药和队列B(N=119)接受一次性注射装置给药。
  • 辅助或新辅助治疗包括含蒽环类方案,随后皮下注射曲妥珠单抗联合紫杉类,之后单药共18个周期。

主要发现

  • 共入组240例患者(辅助治疗81.7%,新辅助治疗18.3%),201例完成治疗(早期停药主要由于并发不良事件,7.5%)。
  • 安全性人群(N=228)中,自皮下注射曲妥珠单抗开始,治疗相关不良事件≥3级发生率为3.9%,严重不良事件为0.9%(一例胸膜心包炎和一例过敏性休克,均已缓解),心脏不良事件为14.5%。
  • 心脏不良事件中最常见为左心室射血分数下降(7.9%;从筛选访视至随访访视平均降低2.9%),未发生充血性心力衰竭。
  • 全身给药相关反应发生率为68.0%,局部注射部位反应为21.9%,大多为1-2级。
  • 两个队列的安全性特征相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subcutaneous trastuzumab (H SC) is a valuable alternative to the intravenous formulation. This study assessed H SC safety and tolerability in human epidermal growth factor receptor 2 (HER2)+ early/locally advanced breast cancer (EBC/LABC). METHODS: SCHEARLY is a prospective, two-cohort, non-randomised, multicentre Italian trial included in the umbrella study UmbHER1, planning a 1-year treatment with H SC 600 mg in HER2+ EBC/LABC. Patients were sequentially assigned to cohort A (N = 121) and B (N = 119) to receive H SC via a handheld syringe and a single-use injection device, respectively. Adjuvant or neoadjuvant treatment included anthracycline-containing regimens followed by H SC plus taxanes and then alone for 18 cycles totally. RESULTS: Two hundred forty patients were enrolled (adjuvant therapy: 81.7%; neoadjuvant therapy: 18.3%), and 201 completed the treatment (early discontinuation was mainly due to intercurrent adverse events [AEs], 7.5%). Overall, the two cohorts displayed similar safety profiles. From H SC start, the rate of treatment-related AEs in the safety population (N = 228) was 3.9% for grade ≥3 AEs; 0.9% for serious AEs (one pleuropericarditis and one anaphylactic shock, both resolved) and 14.5% for cardiac AEs, the most common being the decreased left ventricular ejection fraction (7.9%; mean reduction from the screening to the follow-up visit was 2.9%). No cases of congestive heart failure occurred. The rate of systemic administration-related reactions and local injection site reactions was 68.0% and 21.9%, respectively, mostly of grade 1-2. CONCLUSIONS: H SC 600 mg confirmed to be a safe and tolerable option as adjuvant/neoadjuvant therapy in patients with HER2+ EBC and LABC. CLINICALTRIALS. GOV IDENTIFIER: NCT01940497.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zambetti M, Montemurro F, Morandi P, et al. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. Eur J Cancer. 2018. PMID: 30396014. doi:10.1016/j.ejca.2018.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。